I<SUP>125</SUP> irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis
S. Li,J-H Guo,J. Lu,C. Wang,H. Wu,H. Wang,J. Zha,R. Fan
DOI: https://doi.org/10.1016/j.canrad.2020.12.003
2021-01-01
Abstract:Purpose. - A meta-analysis aimed to systematically evaluate the safety and efficiency of I-125 irradiation stent placement for patients with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT). Materials and methods. - The Cochrane library, PubMed/Medline, EMBASE, CNKI, Wanfang Data and CQVIP were systematically screened out from the earliest to December 2019. The qualities of all included studies were assessed. The primary endpoints were the 6-month, 12 -month stent cumulative patency rate and 6-month, 12-month, 24-month overall survival rate while the secondary endpoints were the objective response rate of PVTT, main portal venous pressure changes and treatment-related adverse events. Our meta-analysis was conducted using Stata 12.0 software. Results. - Totally seven studies with 1018 patients were included in the final analysis, in which 602 patients received TACE and I-125 irradiation stent placement, and 416 patients in control group underwent TACE and stent placement without endovascular brachytherapy (EVBT). Meta-analysis showed that the I-125 irradiation stent improved the cumulative stent patency rates in 6 months [OR= 1.65, 95% CI (1.32-2.05), P<0.001] and 12 months [OR= 2.55, 95% CI (1.90-3.42), P< 0.001] and the survival rates in 6 months [OR= 1.77, 95% CI (1.41-2.22), P< 0.001], 12 months [OR= 3.14, 95% CI (2.24-4.40), P< 0.001] and 24 months [OR= 7.39, 95% CI (3.55-15.41), P< 0.001]. However, there was no difference in the objective response rate of PVTT [OR= 1.13, 95% CI (0.87-1.48), P = 0.365], main portal venous pressure and the occurrence adverse event [OR= 0.88, CI = 0.72-1.08, P= 0.212] between two groups. Conclusion. -I-125 irradiation stent seems to be more effective in treating hepatocellular carcinoma with portal vein tumor thrombosis. The usage of portal vein stent combined endovascular brachytherapy has the potential to act as an alternative therapy for HCC with PVTT. On account of the limitation of studies included, more studies with high-level evidence, such as RCT5, are requisite to support the above promising results. (C) 2020 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).